SYNH
Undervalued by 2.3% based on the discounted cash flow analysis.
Market cap | $4.46 Billion |
---|---|
Enterprise Value | $8.07 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $2.57 |
Beta | 1.58 |
Outstanding Shares | 103,679,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 16.61 |
---|---|
PEG | -16.78 |
Price to Sales | 0.83 |
Price to Book Ratio | 1.3 |
Enterprise Value to Revenue | 1.49 |
Enterprise Value to EBIT | 24.15 |
Enterprise Value to Net Income | 113 |
Total Debt to Enterprise | 0.46 |
Debt to Equity | 1.06 |
No data
No data
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer perfor...